Seeking Alpha

Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for...

Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for wet age-related macular degeneration, were $276M. That's above estimates of $264.2M and brings the total for 2012 to $838M. Regeneron forecasts that U.S. sales will grow 50%, leading to annual revenue of $1.26B and already beating a Citigroup prediction that Eylea would generate peak annual sales of $1.1B in 2021. (Presentation for JPM conference)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector